Glaxosmithkline, LLC has been awarded a $18,161,555 firm fixed price delivery order against the Pandemic Influenza Preparedness and Response 2016-2021 master indefinite delivery indefinite quantity contract by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response. The delivery order is for clinical study services to support development of an AS03B-H7N9 vaccine, with performance at Glaxosmithkline's North Carolina facilities through April 2024. No set-aside designation was applied to this award. The Pandemic Influenza Preparedness and Response 2016-2021 IDIQ, valued at $15 million over five years, supports the agency's efforts to develop medical countermeasures like vaccines against pandemic threats under the auspices of Project BioShield.
Generated 2/29/24, 10:18 AM